The underlying inflammatory chronic disease influences infliximab pharmacokinetics

Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis

(2015) Sarah S. Thomas et al.   BIODRUGS

Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis

(2015) David Ternant et al.   CLINICAL PHARMACOKINETICS

A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS)

(2015) David Ternant et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

A robust estimation of infliximab pharmacokinetic parameters in Crohn’s disease

(2015) Alexandre Aubourg et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

(2015) Johannan F. Brandse et al.   GASTROENTEROLOGY

Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Relationships of Monoclonal Antibodies in Children

(2014) Helena Edlund et al.   CLINICAL PHARMACOKINETICS

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease

(2014) David Ternant et al.   CLINICAL PHARMACOKINETICS

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

(2014) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

(2014) Freddy Cornillie et al.   GUT

Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease

(2014) Iris Dotan et al.   INFLAMMATORY BOWEL DISEASES

Plasma Levels of IL-37 and Correlation with TNF-α, IL-17A, and Disease Activity during DMARD Treatment of Rheumatoid Arthritis

(2014) Ping-Wei Zhao et al.   PLoS One

The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis

(2013) Bart J. F. van den Bemt et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis

(2013) David Ternant et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity

(2013) Rintaro Moroi et al.   IMMUNOGENETICS

P500 Fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease

(2013) J.F. Brandse et al.   Journal of Crohns & Colitis

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

(2012) C. Muller et al.   BLOOD

The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters

(2012) Saloumeh K. Fischer et al.   mAbs

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

(2011) Bart JF van den Bemt et al.   BMC MUSCULOSKELETAL DISORDERS

Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis

(2011) David Ternant et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Population PK and IgE Pharmacodynamic Analysis of a Fully Human Monoclonal Antibody Against IL4 Receptor

(2011) Tarundeep Kakkar et al.   PHARMACEUTICAL RESEARCH

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

(2011) Emilie Ducourau et al.   ARTHRITIS RESEARCH & THERAPY

Transmembrane TNF- : structure, function and interaction with anti-TNF agents

(2010) T. Horiuchi et al.   RHEUMATOLOGY

Trough Infliximab Concentrations Predict Efficacy and Sustained Control of Disease Activity in Rheumatoid Arthritis

(2010) Denis Mulleman et al.   THERAPEUTIC DRUG MONITORING

Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study

(2009) Roman Krzysiek et al.   ARTHRITIS AND RHEUMATISM

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients

(2009) David Ternant et al.   THERAPEUTIC DRUG MONITORING

Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis

(2008) Zhenhua Xu et al.   JOURNAL OF CLINICAL PHARMACOLOGY